Bile Acids

胆汁酸

基本信息

  • 批准号:
    10408684
  • 负责人:
  • 金额:
    $ 3.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-06-15 至 2023-03-18
  • 项目状态:
    已结题

项目摘要

This proposal aims to elucidate how proanthocyanidin-rich extracts of grape polyphenols (GPs) modulate bile acid (BA) signaling to farnesoid X-receptor (FXR) resulting in improved glucose metabolism. Using intestine- specific (FxrΔIE) and liver-specific (FxrΔL) FXR knockout mice and derived ileal organoids, we will investigate whether GP-induced glycemic improvements are due to inhibition of intestinal and/or hepatic FXR signaling. We will also determine if GPs directly sequester secondary bile acids (SBAs) or indirectly leads to their depletion. Consumption of polyphenol-rich foods is associated with reduced risk of chronic disease; however, many dietary polyphenols are poorly absorbed raising questions about their mechanism(s) of action. Metabolic benefits of polyphenols are likely driven by changes in the gut microbiota. Prior work showed that GPs improved glucose metabolism in high-fat diet (HFD)-fed wild type (WT) mice due to GP-induced changes in the gut microbiota that correlated with attenuated body weight, metabolic endotoxemia (i.e. lower serum lipopolysaccharide (LPS)), tissue inflammation, as well as increased tight junction protein expression. Our recent data showed that GP supplementation mitigated hyperglycemia in diabetic db/db mice independent of changes in obesity, gut barrier integrity, and inflammation. Rather, GP-induced changes in the gut microbiota of db/db mice promoted a BA profile that suppressed intestinal FXR activity and FXR responsive pathways. Selective inhibition of intestinal FXR has been correlated with improved glucose metabolism and decreased ceramide synthesis in mice treated with antidiabetic drug, metformin. Metformin altered the gut microbiota and BA pool, reduced ceramide production, and lowered expression of hepatic gluconeogenic markers [Sun et al., 2018]. Dual antagonism of FXR in liver and intestine may promote cholestasis [Kong et al., 2012], therefore differentiating tissue specific effects of GPs on FXR activity is important. 16S rRNA V4 amplicon sequencing showed that GP supplementation depleted genera implicated in secondary BA (SBAs) metabolism concomitant with a dramatic decrease in serum SBAs and an increase in primary BAs (PBAs). Intestinal and liver tissues of mice supplemented with GPs had: 1) decreased gene expression of Shp and Fgf15, markers of FXR activity; 2) lowered expression of Smpd3, Cers4, and Sptlc2 , FXR responsive genes critical for ceramide synthesis; and 3) increased expression of Cyp7a1, an enzyme responsible for PBA synthesis. Gut organoids were used to differentiate the direct effects of BAs on intestinal FXR activation and ceramide synthesis and revealed GP-induced a BA profile antagonistic to intestinal FXR. We propose to 1) investigate glucoregulatory effect of GP supplementation in FxrΔIE and FxrΔL to uncover if GPs are antagonistic to liver FXR signaling mechanisms and distinguish the ability of GPs to sequester SBAs agonistic to FXR within the ileum. 2) Use ileal gut organoids derived from FXR∆IE to determine the requirement of intestinal FXR for GP-mediated regulation of ceramide biosynthesis and 3) directly determine whether anaerobic cultures of ileal content collected from GP supplemented mice lack ability to produce SBAs.
本研究旨在阐明富含原花青素的葡萄多酚提取物如何调节胆汁 酸(BA)信号传导至法尼醇X-受体(FXR),导致改善的葡萄糖代谢。利用肠子- 特异性(FxrΔIE)和肝脏特异性(FxrΔL)FXR敲除小鼠和衍生的回肠类器官,我们将研究 GP诱导的血糖改善是否是由于肠和/或肝FXR信号传导的抑制。我们 还将确定GP是否直接螯合二级胆汁酸(SBA)或间接导致其耗尽。 食用富含多酚的食物与降低慢性疾病的风险有关;然而,许多饮食 多酚的吸收较差,这引起了关于其作用机制的问题。代谢益处 多酚可能是由肠道微生物群的变化驱动的。先前的研究表明,全科医生改善葡萄糖 由于GP诱导的肠道微生物群的变化, 与体重减轻、代谢性内毒素血症(即血清脂多糖(LPS)降低)、 组织炎症以及紧密连接蛋白表达增加。我们最近的数据显示, 补充可减轻糖尿病db/db小鼠高血糖,与肥胖、肠屏障 完整性和炎症相反,GP诱导的db/db小鼠肠道微生物群的变化促进了BA 抑制肠道FXR活性和FXR应答途径的特征。选择性肠抑制 FXR与治疗小鼠的葡萄糖代谢改善和神经酰胺合成减少相关 抗糖尿病药物二甲双胍代谢物改变了肠道微生物群和BA池,减少了神经酰胺 产生,并降低肝致坏死标志物的表达[Sun等人,2018年]。双重拮抗 肝和肠中的FXR可促进胆汁淤积[Kong等人,2012年],因此区分组织特异性 GP对FXR活性的影响是重要的。16 S rRNA V4扩增子测序显示,GP补充 与次级BA(SBAs)代谢有关的耗尽的属伴随着血清中BA水平的急剧下降, SBAs和主要BA(PBAs)的增加。补充GP的小鼠的肠道和肝脏组织具有: 1)FXR活性标志物Shp和Fgf 15的基因表达降低; 2)Smpd 3的表达降低, Cers 4和Sptlc 2,对神经酰胺合成至关重要的FXR应答基因;和3)增加的 Cyp 7a 1,一种负责PBA合成的酶。肠道类器官用于区分直接作用 的BA对肠道FXR激活和神经酰胺合成的影响,并揭示了GP诱导的BA拮抗作用。 肠道FXR。我们的研究目的是:1)研究GP对FxrΔIE和FxrΔL的糖调节作用 揭示GPs是否拮抗肝脏FXR信号传导机制,并区分GPs 将对FXR激动的SBA隔离在回肠内。2)使用源自FXR消化道的回肠肠类器官来确定 肠FXR对GP介导调节神经酰胺生物合成的需要,以及3)直接确定 从补充GP的小鼠收集的回肠内容物的厌氧培养物是否缺乏产生SBA的能力。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Grape Polyphenols May Prevent High-Fat Diet-Induced Dampening of the Hypothalamic-Pituitary-Adrenal Axis in Male Mice.
  • DOI:
    10.1210/jendso/bvad095
  • 发表时间:
    2023-08-01
  • 期刊:
  • 影响因子:
    4.1
  • 作者:
    Mezhibovsky, Esther;Tveter, Kevin M.;Villa-Rodriguez, Jose A.;Bacalia, Karen;Kshatriya, Dushyant;Desai, Nikhil;Cabales, Alrick;Wu, Yue;Sui, Ke;Duran, Rocio M.;Bello, Nicholas T.;Roopchand, Diana E.
  • 通讯作者:
    Roopchand, Diana E.
Impact of grape polyphenols on Akkermansia muciniphila and the gut barrier.
  • DOI:
    10.3934/microbiol.2022035
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Mezhibovsky E;Wu Y;Bawagan FG;Tveter KM;Szeto S;Roopchand D
  • 通讯作者:
    Roopchand D
Grape Polyphenols Attenuate Diet-Induced Obesity and Hepatic Steatosis in Mice in Association With Reduced Butyrate and Increased Markers of Intestinal Carbohydrate Oxidation.
  • DOI:
    10.3389/fnut.2021.675267
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    5
  • 作者:
    Mezhibovsky E;Knowles KA;He Q;Sui K;Tveter KM;Duran RM;Roopchand DE
  • 通讯作者:
    Roopchand DE
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kevin Michael Tveter其他文献

Kevin Michael Tveter的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 3.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 3.59万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 3.59万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 3.59万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 3.59万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 3.59万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 3.59万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 3.59万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 3.59万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 3.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了